Novavax, influenza vaccine and FDA
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The company in May had signed a deal worth at least $1.2 billion with Sanofi to co-sell Novavax's vaccine in most countries and use the COVID shot along with its own flu vaccines to develop a ...
Novavax said a participant enrolled in a mid stage study of the combination vaccine last month reported symptoms of motor ...
Flu season is emerging and, although the disease is not predicted to be as prominent as years past, doctors urge people to ...
Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.